Davis Polk is advising Shire plc on its acquisition of Lotus Tissue Repair, Inc. Subject to customary government approvals, Shire will purchase Lotus Tissue Repair for an upfront payment and certain contingent payments based on the achievement of certain safety and development milestones.
Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Lotus Tissue Repair is a Cambridge, Massachusetts-based, privately held biotechnology company developing the first and only protein replacement therapy currently being investigated for the treatment of dystrophic epidermolysis bullosa.
The Davis Polk corporate team includes partner William J. Chudd and associates Brian Wolfe and Ashley M. Bryant. Partner Kyoko Takahashi Lin and associates Andrew Blau and Jessica Lutrin are providing benefits advice. Partner Frank J. Azzopardi and associate David R. Bauer are providing intellectual property advice. Partner Michael Mollerus and associate Arie Rubenstein are providing tax advice. All members of the Davis Polk team are based in the New York office.
